PortfoliosLab logo

ProShares Ultra Nasdaq Biotechnology (BIB)

ETF · Currency in USD · Last updated Jun 23, 2022

BIB is a passive ETF by ProShares tracking the investment results of the NASDAQ Biotechnology Index (200%). BIB launched on Apr 7, 2010 and has a 0.95% expense ratio.

ETF Info

Inception DateApr 7, 2010
RegionNorth America (U.S.)
CategoryLeveraged Equities, Leveraged
Expense Ratio0.95%
Index TrackedNASDAQ Biotechnology Index (200%)
ETF Home Pagewww.proshares.com
Asset ClassEquity

Asset Class Size


Asset Class Style


Trading Data

Previous Close$45.93
Year Range$39.29 - $110.40
EMA (50)$48.88
EMA (200)$67.87
Average Volume$40.16K

BIBShare Price Chart

Chart placeholderClick Calculate to get results


The chart shows the growth of $10,000 invested in ProShares Ultra Nasdaq Biotechnology on Apr 9, 2010 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $61,253 for a total return of roughly 512.53%. All prices are adjusted for splits and dividends.

BIB (ProShares Ultra Nasdaq Biotechnology)
Benchmark (^GSPC)

BIBReturns in periods

Returns over 1 year are annualized


BIBMonthly Returns Heatmap

Chart placeholderClick Calculate to get results

BIBSharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current ProShares Ultra Nasdaq Biotechnology Sharpe ratio is -0.98. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

BIB (ProShares Ultra Nasdaq Biotechnology)
Benchmark (^GSPC)

BIBDividend History

ProShares Ultra Nasdaq Biotechnology granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.


Dividend yield


BIBDrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.

BIB (ProShares Ultra Nasdaq Biotechnology)
Benchmark (^GSPC)

BIBWorst Drawdowns

The table below shows the maximum drawdowns of the ProShares Ultra Nasdaq Biotechnology. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the ProShares Ultra Nasdaq Biotechnology is 67.24%, recorded on Jun 27, 2016. It took 1152 trading sessions for the portfolio to recover.



To Bottom


To Recover



-67.24%Jul 21, 2015237Jun 27, 20161152Jan 25, 20211389
-64.76%Feb 9, 2021339Jun 13, 2022
-41.45%May 13, 201160Aug 8, 2011112Jan 18, 2012172
-39.01%Feb 26, 201433Apr 11, 2014114Sep 24, 2014147
-36.3%Apr 16, 201048Jul 1, 201093Dec 17, 2010141
-24.73%Oct 8, 201227Nov 15, 201271Mar 1, 201398
-20.33%May 15, 201326Jun 20, 201314Jul 11, 201340
-17.74%Mar 23, 201528Apr 30, 201534Jun 18, 201562
-17.57%Oct 2, 20136Oct 9, 201332Nov 22, 201338
-16.83%Sep 25, 201414Oct 14, 20147Oct 23, 201421

BIBVolatility Chart

Current ProShares Ultra Nasdaq Biotechnology volatility is 97.80%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.

BIB (ProShares Ultra Nasdaq Biotechnology)
Benchmark (^GSPC)

Portfolios with ProShares Ultra Nasdaq Biotechnology

Loading data...